The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses

The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses

Abstract Mitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non‐alcoholic steatohepatits and chronic obstructive pulmonary disease. We aimed to assess the risk of QT‐interval prolongation...

Full description

Bibliographic Details
Main Authors: Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Pharmacology Research & Perspectives
Subjects:
biopharmaceutics
drug safety
heart failure
modeling and simulation
QT prolongation
Online Access:https://doi.org/10.1002/prp2.1184

Internet

https://doi.org/10.1002/prp2.1184

Similar Items